Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2015 | Pages:
240 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Pseudomonas Aeruginosa Infections - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Pseudomonas Aeruginosa Infections - Pipeline Review, H2 2015', provides an overview of the Pseudomonas Aeruginosa Infections's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Pseudomonas Aeruginosa Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pseudomonas Aeruginosa Infections and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Pseudomonas Aeruginosa Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Pseudomonas Aeruginosa Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Pseudomonas Aeruginosa Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Pseudomonas Aeruginosa Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Pseudomonas Aeruginosa Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Pseudomonas Aeruginosa Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Pseudomonas Aeruginosa Infections Overview 11 Therapeutics Development 12 Pipeline Products for Pseudomonas Aeruginosa Infections - Overview 12 Pipeline Products for Pseudomonas Aeruginosa Infections - Comparative Analysis 13 Pseudomonas Aeruginosa Infections - Therapeutics under Development by Companies 14 Pseudomonas Aeruginosa Infections - Therapeutics under Investigation by Universities/Institutes 19 Pseudomonas Aeruginosa Infections - Pipeline Products Glance 20 Late Stage Products 20 Clinical Stage Products 21 Early Stage Products 22 Unknown Stage Products 23 Pseudomonas Aeruginosa Infections - Products under Development by Companies 24 Pseudomonas Aeruginosa Infections - Products under Investigation by Universities/Institutes 29 Pseudomonas Aeruginosa Infections - Companies Involved in Therapeutics Development 30 Achaogen Inc. 30 Adenium Biotech ApS 31 Aeolus Pharmaceuticals, Inc. 32 AlgiPharma AS 33 AmpliPhi Biosciences Corporation 34 AnGes MG, Inc. 35 Arch Biopartners, Inc. 36 Aridis Pharmaceuticals LLC 37 Arno Therapeutics, Inc. 38 AstraZeneca Plc 39 Biolytics Pharma 40 CSA Biotechnologies LLC 41 Evaxion Biotech 42 F. Hoffmann-La Roche Ltd. 43 FOB Synthesis, Inc. 44 GlaxoSmithKline Plc 45 GlycoMimetics, Inc. 46 Helix BioMedix, Inc. 47 Hsiri Therapeutics, LLC 48 Insmed Incorporated 49 Lascco SA 50 LegoChem Biosciences, Inc 51 Lytix Biopharma AS 52 MedImmune, LLC 53 Melinta Therapeutics, Inc 54 Microbiotix, Inc. 55 MicuRx Pharmaceuticals, Inc. 56 Nosopharm SAS 57 Novabiotics Limited 58 Novan, Inc. 59 Omnia Molecular Ltd. 60 Pfizer Inc. 61 Pherecydes Pharma SA 62 Phico Therapeutics Limited 63 Phylogica Limited 64 Polyphor Ltd. 65 Sanofi 66 Sarepta Therapeutics, Inc. 67 Sealife PHARMA GMBH 68 Sequoia Sciences, Inc. 69 Shionogi & Co., Ltd. 70 Soligenix, Inc. 71 Syntiron LLC 72 Tetraphase Pharmaceuticals Inc. 73 Trana Discovery, Inc. 74 Valneva SE 75 Varinel, Inc. 76 Vaxdyn, S.L. 77 Zambon Company S.p.A. 78 Pseudomonas Aeruginosa Infections - Therapeutics Assessment 79 Assessment by Monotherapy Products 79 Assessment by Combination Products 80 Assessment by Target 81 Assessment by Mechanism of Action 83 Assessment by Route of Administration 85 Assessment by Molecule Type 87 Drug Profiles 89 (fosfomycin + tobramycin) - Drug Profile 89 AA-139 - Drug Profile 90 AB-569 - Drug Profile 91 ABPA-01 - Drug Profile 92 ACHN-975 Prodrug - Drug Profile 94 AEOL-20415 - Drug Profile 95 Aerucin - Drug Profile 96 AG-30/5C - Drug Profile 97 AGL-503 - Drug Profile 98 amikacin sulphate - Drug Profile 99 Antibiotics to Inhibit tRNA For Hospital-Acquired Gram-Negative Bacterial Infections - Drug Profile 104 Antisense Oligonucleotide for Drug Resistant Pseudomonas Aeruginosa Infections - Drug Profile 105 AR-104 - Drug Profile 106 AR-13 - Drug Profile 107 Biologic for Pseudomonas Aeruginosa Infection - Drug Profile 108 CAL-02 - Drug Profile 109 Cell Therapy for GBM and Pseudomonas Aeruginosa Infections - Drug Profile 110 Cephalosporin + Beta-Lactamase Inhibitor - Drug Profile 111 CSA-13 - Drug Profile 112 dehydroleucodine - Drug Profile 113 dusquetide - Drug Profile 114 EBX-001 - Drug Profile 116 FSI-1671 - Drug Profile 117 FSI-1686 - Drug Profile 118 G-10 - Drug Profile 119 GMI-1051 - Drug Profile 120 GN snare - Drug Profile 121 GN-4474 - Drug Profile 122 HB-1345 - Drug Profile 123 HT-05 - Drug Profile 124 KBP-7963 - Drug Profile 125 LCB-100200 - Drug Profile 126 LTX-109 - Drug Profile 127 MBX-2359 - Drug Profile 129 MBX-2402 - Drug Profile 130 MDN-0057 - Drug Profile 131 Monoclonal Antibodies for Gram-Negative Bacterial Infections - Drug Profile 133 MRX-V - Drug Profile 134 NBTI-5463 - Drug Profile 135 NOSO-95179 - Drug Profile 136 NP-432 - Drug Profile 137 NVN-1000 - Drug Profile 138 Oligomer G for Pseudomonas Aeruginosa and Candida Infectious - Drug Profile 139 OM-011818 - Drug Profile 140 Panaecin - Drug Profile 141 POL-7080 Follow-On - Drug Profile 143 PP-1131 - Drug Profile 144 PP-1231 - Drug Profile 146 pseudomonas + VAP vaccine - Drug Profile 147 Pseudomonas aeruginosa vaccine - Drug Profile 148 Pseudomonas aeruginosa vaccine - Drug Profile 149 Pseudomonas aeruginosa vaccine - Drug Profile 150 Pseudomonas aeruginosa vaccine - Drug Profile 151 pseudomonas vaccine - Drug Profile 152 PT-3.1 - Drug Profile 153 PT-3.33 - Drug Profile 154 Recombinant Protein for Pseudomonas Aeruginosa Infections - Drug Profile 155 Recombinant Proteins for Pseudomonas aeruginosa Infection - Drug Profile 156 RX-05 - Drug Profile 157 RXP-763 - Drug Profile 158 RXP-766 - Drug Profile 160 RXP-770 - Drug Profile 162 RXP-792 - Drug Profile 164 RXP-793 - Drug Profile 165 RXP-808 - Drug Profile 166 RXP-873 - Drug Profile 167 S-649266 - Drug Profile 168 SLP-0901 - Drug Profile 169 Small Molecule 2 to Inhibit Lectin B for Pseudomonas Aeruginosa Infections - Drug Profile 170 Small Molecule for Gram-Negative Nosocomial Infections - Drug Profile 171 Small Molecule to Inhibit Lectins for Pseudomonas Infections - Drug Profile 172 Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections - Drug Profile 173 Small Molecules for Bacterial Infections - Drug Profile 174 Small Molecules for Gram-Negative Bacterial Infections - Drug Profile 175 Small Molecules for Gram-Negative Bacterial Infections and Pseudomonas Aeruginosa Infections - Drug Profile 176 Small Molecules for Multi-Drug Resistant Bacterial Infections - Drug Profile 177 Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Drug Profile 178 Small Molecules for Resistant Pseudomonas aeruginosa Infections - Drug Profile 179 Small Molecules to Inhibit LasB for Pseudomonas Aeruginosa Infections - Drug Profile 180 Small Molecules to Inhibit LasR Receptor for Lung Infections and Pseudomonas aeruginosa Infections - Drug Profile 181 Small Molecules to Inhibit Lectin B for Pseudomonas Aeruginosa Infections - Drug Profile 182 Small Molecules to Inhibit LpxC for Gram-Negative Bacterial Infections - Drug Profile 183 Small Molecules to Inhibit MvfR for Pseudomonas aeruginosa Infections - Drug Profile 184 Small Molecules to Inhibit PqsD for Pseudomonas Aeruginosa Infections - Drug Profile 185 Small Molecules to Inhibit T3SS for Pseudomonas Aeruginosa Infections - Drug Profile 186 Small Molecules to Inhibit the Fatty Acid Synthesis for Pseudomonas Aeruginosa Infections - Drug Profile 187 Synthetic Peptide for Gram-Negative Bacterial Infections - Drug Profile 189 Synthetic Peptide to Antagonize TLR-4 for Oncology, Immunology and Infectious Disease - Drug Profile 190 TP-433 - Drug Profile 191 TP-559 - Drug Profile 192 TP-6076 - Drug Profile 193 V-2L2MD - Drug Profile 194 VAR-10100 - Drug Profile 195 VLA-43 - Drug Profile 196 VXD-002 - Drug Profile 198 ZP-044 - Drug Profile 199 ZP-046 - Drug Profile 200 Pseudomonas Aeruginosa Infections - Recent Pipeline Updates 201 Pseudomonas Aeruginosa Infections - Dormant Projects 219 Pseudomonas Aeruginosa Infections - Discontinued Products 223 Pseudomonas Aeruginosa Infections - Product Development Milestones 224 Featured News & Press Releases 224 Appendix 232 Methodology 232 Coverage 232 Secondary Research 232 Primary Research 232 Expert Panel Validation 232 Contact Us 232 Disclaimer 233
List of Tables
Number of Products under Development for Pseudomonas Aeruginosa Infections, H2 2015 19 Number of Products under Development for Pseudomonas Aeruginosa Infections - Comparative Analysis, H2 2015 20 Number of Products under Development by Companies, H2 2015 22 Number of Products under Development by Companies, H2 2015 (Contd..1) 23 Number of Products under Development by Companies, H2 2015 (Contd..2) 24 Number of Products under Development by Companies, H2 2015 (Contd..3) 25 Number of Products under Investigation by Universities/Institutes, H2 2015 26 Comparative Analysis by Late Stage Development, H2 2015 27 Comparative Analysis by Clinical Stage Development, H2 2015 28 Comparative Analysis by Early Stage Development, H2 2015 29 Comparative Analysis by Unknown Stage Development, H2 2015 30 Products under Development by Companies, H2 2015 31 Products under Development by Companies, H2 2015 (Contd..1) 32 Products under Development by Companies, H2 2015 (Contd..2) 33 Products under Development by Companies, H2 2015 (Contd..3) 34 Products under Development by Companies, H2 2015 (Contd..4) 35 Products under Investigation by Universities/Institutes, H2 2015 36 Pseudomonas Aeruginosa Infections - Pipeline by Achaogen Inc., H2 2015 37 Pseudomonas Aeruginosa Infections - Pipeline by Adenium Biotech ApS, H2 2015 38 Pseudomonas Aeruginosa Infections - Pipeline by Aeolus Pharmaceuticals, Inc., H2 2015 39 Pseudomonas Aeruginosa Infections - Pipeline by AlgiPharma AS, H2 2015 40 Pseudomonas Aeruginosa Infections - Pipeline by AmpliPhi Biosciences Corporation, H2 2015 41 Pseudomonas Aeruginosa Infections - Pipeline by AnGes MG, Inc., H2 2015 42 Pseudomonas Aeruginosa Infections - Pipeline by Arch Biopartners, Inc., H2 2015 43 Pseudomonas Aeruginosa Infections - Pipeline by Aridis Pharmaceuticals LLC, H2 2015 44 Pseudomonas Aeruginosa Infections - Pipeline by Arno Therapeutics, Inc., H2 2015 45 Pseudomonas Aeruginosa Infections - Pipeline by AstraZeneca Plc, H2 2015 46 Pseudomonas Aeruginosa Infections - Pipeline by Biolytics Pharma, H2 2015 47 Pseudomonas Aeruginosa Infections - Pipeline by CSA Biotechnologies LLC , H2 2015 48 Pseudomonas Aeruginosa Infections - Pipeline by Evaxion Biotech, H2 2015 49 Pseudomonas Aeruginosa Infections - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 50 Pseudomonas Aeruginosa Infections - Pipeline by FOB Synthesis, Inc., H2 2015 51 Pseudomonas Aeruginosa Infections - Pipeline by GlaxoSmithKline Plc, H2 2015 52 Pseudomonas Aeruginosa Infections - Pipeline by GlycoMimetics, Inc., H2 2015 53 Pseudomonas Aeruginosa Infections - Pipeline by Helix BioMedix, Inc., H2 2015 54 Pseudomonas Aeruginosa Infections - Pipeline by Hsiri Therapeutics, LLC, H2 2015 55 Pseudomonas Aeruginosa Infections - Pipeline by Insmed Incorporated, H2 2015 56 Pseudomonas Aeruginosa Infections - Pipeline by Lascco SA, H2 2015 57 Pseudomonas Aeruginosa Infections - Pipeline by LegoChem Biosciences, Inc, H2 2015 58 Pseudomonas Aeruginosa Infections - Pipeline by Lytix Biopharma AS, H2 2015 59 Pseudomonas Aeruginosa Infections - Pipeline by MedImmune, LLC, H2 2015 60 Pseudomonas Aeruginosa Infections - Pipeline by Melinta Therapeutics, Inc, H2 2015 61 Pseudomonas Aeruginosa Infections - Pipeline by Microbiotix, Inc., H2 2015 62 Pseudomonas Aeruginosa Infections - Pipeline by MicuRx Pharmaceuticals, Inc., H2 2015 63 Pseudomonas Aeruginosa Infections - Pipeline by Nosopharm SAS, H2 2015 64 Pseudomonas Aeruginosa Infections - Pipeline by Novabiotics Limited, H2 2015 65 Pseudomonas Aeruginosa Infections - Pipeline by Novan, Inc., H2 2015 66 Pseudomonas Aeruginosa Infections - Pipeline by Omnia Molecular Ltd., H2 2015 67 Pseudomonas Aeruginosa Infections - Pipeline by Pfizer Inc., H2 2015 68 Pseudomonas Aeruginosa Infections - Pipeline by Pherecydes Pharma SA, H2 2015 69 Pseudomonas Aeruginosa Infections - Pipeline by Phico Therapeutics Limited, H2 2015 70 Pseudomonas Aeruginosa Infections - Pipeline by Phylogica Limited, H2 2015 71 Pseudomonas Aeruginosa Infections - Pipeline by Polyphor Ltd., H2 2015 72 Pseudomonas Aeruginosa Infections - Pipeline by Sanofi, H2 2015 73 Pseudomonas Aeruginosa Infections - Pipeline by Sarepta Therapeutics, Inc., H2 2015 74 Pseudomonas Aeruginosa Infections - Pipeline by Sealife PHARMA GMBH, H2 2015 75 Pseudomonas Aeruginosa Infections - Pipeline by Sequoia Sciences, Inc., H2 2015 76 Pseudomonas Aeruginosa Infections - Pipeline by Shionogi & Co., Ltd., H2 2015 77 Pseudomonas Aeruginosa Infections - Pipeline by Soligenix, Inc., H2 2015 78 Pseudomonas Aeruginosa Infections - Pipeline by Syntiron LLC, H2 2015 79 Pseudomonas Aeruginosa Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2015 80 Pseudomonas Aeruginosa Infections - Pipeline by Trana Discovery, Inc., H2 2015 81 Pseudomonas Aeruginosa Infections - Pipeline by Valneva SE, H2 2015 82 Pseudomonas Aeruginosa Infections - Pipeline by Varinel, Inc., H2 2015 83 Pseudomonas Aeruginosa Infections - Pipeline by Vaxdyn, S.L., H2 2015 84 Pseudomonas Aeruginosa Infections - Pipeline by Zambon Company S.p.A., H2 2015 85 Assessment by Monotherapy Products, H2 2015 86 Assessment by Combination Products, H2 2015 87 Number of Products by Stage and Target, H2 2015 89 Number of Products by Stage and Mechanism of Action, H2 2015 91 Number of Products by Stage and Route of Administration, H2 2015 93 Number of Products by Stage and Molecule Type, H2 2015 95 Pseudomonas Aeruginosa Infections Therapeutics - Recent Pipeline Updates, H2 2015 208 Pseudomonas Aeruginosa Infections - Dormant Projects, H2 2015 226 Pseudomonas Aeruginosa Infections - Dormant Projects (Contd..1), H2 2015 227 Pseudomonas Aeruginosa Infections - Dormant Projects (Contd..2), H2 2015 228 Pseudomonas Aeruginosa Infections - Dormant Projects (Contd..3), H2 2015 229 Pseudomonas Aeruginosa Infections - Discontinued Products, H2 2015 230
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
